Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi

Scrip offers some key points to watch for as the biopharmaceutical sales and earnings start to roll in. While the pricing debate in the US may have lost some steam, the negative impact of pricing pressure on J&J's pharma sales have analysts concerned.

Sales & Earnings Companies Business Strategies

Pursuing Productive Pharma Partnerships In Korea

Multinational and domestic pharma companies operating in South Korea should develop partnerships that build on each others’ strengths, delegates at a recent conference in Seoul heard.

South Korea Research and Development Strategies Deals

New Active Substance Launches Declined Again In 2016

2016 witnessed a second straight year of decline in the number of new active substance launches worldwide, but trend data show that this hard measure of R&D productivity was still healthy compared with industry's performance during the first decade of the century.

Research & Development Companies Analysis

Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market

The third IL-17 inhibitor on the US market will have a $3,500/month list price. But in a crowded, safety-conscious space like psoriasis, it's unclear how low the discounted price will need to go and whether competitive pricing would be enough to sway prescribers.

Pricing Strategies Inflammation Commercial
Advertisement


 Recent Tweets from Scrip


Commercial Explore this Topic

White Flag Raised: UniQure Gives Up On Glybera, But Not Gene Therapies

UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.

Commercial Business Strategies Manufacturing

Noxxon CEO Talks Partnering Strategy & Cancer Combos

Aram Mangasarian, CEO of Noxxon Pharma, a biotech company focused on cancer therapies targeting the tumor microenvironment, discusses partnering options and his strategy for how Noxxon can compete in the busy immuno-oncology space.

StartUps and SMEs Cancer ImmunoOncology

Latest From Commercial

Multispecific Approach Could Improve I-O Side Effect Profile, Says Numab

Multispecific antibody therapeutic developer Numab – run by two former Esbatech executives – has come of age with a deal in the IO space that validates its technology. Could this mean bispecific programs have had their day?

Commercial Companies

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.

Cardiovascular Reimbursement

Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair

Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.

Respiratory Generic Drugs

Motif A Step Closer To Succeeding With Iclaprim After Phase III Success

Biotech firm hopes its once-shelved antibiotic will provide a therapeutic option for renally impaired patients with serious skin infections. With only one previous DHFR inhibitor ever approved, Motif also anticipates that iclaprim will offer an option for multidrug-resistant infections.

Business Strategies Clinical Trials

Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales

Johnson & Johnson had to offer steeper discounts in certain therapeutic categories like cardiovascular and metabolic disease, impacting first quarter sales. So far, the impact of a new biosimilar in the US has had minimal impact on Remicade.

Pricing Strategies Sales & Earnings

Biomunex CEO On Earlier Deals For Cancer Drugs

Biomunex CEO Pierre Emmanuel Gerard discusses the company's founding, its pipeline of innovative bispecific antibodies being developed for oncological indications, and the partnering potential for these compounds.

StartUps and SMEs Cancer

Policy & Regulation Explore this Topic

Forward Pharma Faces Uphill Struggle Appealing Biogen's Tecfidera PTAB Win

Forward Pharma is suspending all FP187 development pending the outcome of its legal interference appeal against Biogen – but analysts see little prospect of it overturning last month's decision that effectively allows Biogen's dimethyl fumarate-based drug Tecfidera to stay on the market with its own patent.

Business Strategies Commercial Companies

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.

Cardiovascular Reimbursement

India Pricing Authority Chief Says List Is No Attempt To Vilify Industry

The chair of India’s National Pharmaceutical Pricing Authority has tried to clear the air around the regulator’s recent public notice that lists over 600 products suspected of having flouted price caps, telling Scrip the chances of error around the data used to verify compliance is low, though at least half a dozen companies on the list indicate they have complied with the regulator’s norms.

India Pricing Debate

Biosimilar Product Differences Will Affect US Uptake, Amgen Predicts

Differences in product characteristics should be considered in formulary decisions, Amgen says in annual trends report that puts its biosimilars in a strong competitive light while also bolstering the position of its reference biologics.

Biosimilars Biologics

Research & Development Explore this Topic

Pipeline Watch: Dismay With Veliparib, Tarextumab, House Dust Mite Allergens

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals Research & Development

Latest From Research & Development

Veliparib Phase III Failures Strike Blow To AbbVie's Oncology Strategy

The failure of veliparib in Phase III studies of squamous NSCLC and triple-negative breast cancer is a blow for AbbVie's oncology pipeline, but may not have implications for other PARP inhibitors in new tumor types.

Clinical Trials Companies

AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients

Data from EXPEDITION-1 show a 99% SVR rate for HCV patients with compensated cirrhosis after 12 weeks of therapy. AbbVie also will present data at EASL on the utility of glecaprevir/pibrentasvir in CKD, post-liver or kidney transplant, HIV co-infected and treatment-failure patients.

Clinical Trials Research & Development

Will Ultragenyx/Kyowa Hypophosphatemia Data Support Uptake?

Ultragenyx and partner Kyowa Hakko Kirin said burosumab (KRN23) met the primary endpoint regarding phosphate levels in a Phase III study that enrolled adult X-linked hypophosphatemia patients, but small effects on two out of three secondary endpoints could impact the product's use.

Clinical Trials Rare Diseases
UsernamePublicRestriction

Register